Abstract 42P
Background
Immunotherapies targeting immune checkpoints have gained increasing attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular RNAs have emerged as critical regulators of tumor immunity, particularly in the PD-(L)1 pathway, and have shown potential in predicting the efficacy of immunotherapies. Therefore, the development of a comprehensive resource that integrates circRNA profiles, immunotherapy response data, and clinical benefits is crucial for advancing our understanding of circRNA-mediated tumor-immune interactions and developing effective immunotherapy biomarkers.
Methods
To address these gaps, we constructed the Cancer CircRNA Immunome Atlas (TCCIA), the first database that combines circRNA profiles, immunotherapy response data, and clinical outcomes across multi-cancer types. The construction of TCCIA involved applying standardized preprocessing to the raw sequencing FASTQ files, characterizing circRNA profiles using CIRCexplorer2, analyzing tumor immunophenotypes through IOBR, and compiling immunotherapy response data from diverse cohorts treated with ICBs.
Results
TCCIA encompasses over 3,700 clinical samples obtained from 18 cohorts treated with ICBs, including PD-1/PD-L1 and CTLA-4 inhibitors, along with other treatment modalities. The database provides researchers and clinicians with a cloud-based platform that enables interactive exploration of circRNA data in the context of ICB. The platform offers a range of analytical tools, including visualization of circRNA abundance and correlation, association analysis between circRNAs and clinical variables, assessment of the tumor immune microenvironment, exploration of tumor molecular signatures, evaluation of treatment response or prognosis, and identification of altered circRNAs in immunotherapy-sensitive and resistant tumors. To illustrate the utility, we performed a re-analysis on a melanoma cohort with TCCIA and found that an isoform of circTMTC3 played a significant role in predicting unfavorable survival outcomes and treatment nonresponse.
Conclusions
TCCIA represents a significant advancement over existing resources, providing a comprehensive platform to investigate the role of circRNAs in immune oncology.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display